Tianjin Medical University Cancer Institute and Hospital, 1 Huanhuxi Road, Hexi District, Tianjin 300060. China.
Curr Gene Ther. 2017;16(6):390-400. doi: 10.2174/1566523217666170215154755.
Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
基因转移和溶瘤病毒为血液系统恶性肿瘤的治疗提供了新的治疗方法。然而，将基因传递或溶瘤病毒引入标准临床方案还为时过早。讨论基因转移和溶瘤病毒治疗血液系统恶性肿瘤的临床应用所面临的障碍，并更新克服这些障碍的进展非常重要。本综述主要关注的问题包括为白血病治疗开发免疫刺激性基因转移介导的疫苗的方法、基于 RNAi 的白血病治疗以及增强靶恶性细胞对病毒治疗的敏感性和改变宿主免疫反应以有利于溶瘤病毒的方法。我们对基因治疗和溶瘤病毒治疗血液系统恶性肿瘤的未来进行了展望，强调了我们应该解决的问题和进一步临床应用的技术要求。
